News | March 31, 2026
Granules Life Sciences receives VAI Classification for Shamirpet facility
The inspection is now closed, and no regulatory action has been recommended
The inspection is now closed, and no regulatory action has been recommended
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Subscribe To Our Newsletter & Stay Updated
